人表皮生长因子受体2阳性转移性乳腺癌仍然是一种无法治愈的疾病吗？ - Suppr

Is HER2-positive metastatic breast cancer still an incurable disease?

作者信息

Lambertini Matteo, Vaz-Luis Ines

机构信息

Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, 16132 Italy.

Department of Medical Oncology, Institut Gustave Roussy, Université Paris-Saclay, Inserm, Biomarqueurs Prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, Villejuif, France.

出版信息

Lancet Oncol. 2020 Apr;21(4):471-472. doi: 10.1016/S1470-2045(20)30058-9. Epub 2020 Mar 12.

DOI:10.1016/S1470-2045(20)30058-9

PMID:32171427

Abstract

摘要

相似文献

Is HER2-positive metastatic breast cancer still an incurable disease?

Lancet Oncol. 2020 Apr;21(4):471-472. doi: 10.1016/S1470-2045(20)30058-9. Epub 2020 Mar 12.

Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.

Expert Rev Anticancer Ther. 2015 Jan;15(1):17-26. doi: 10.1586/14737140.2015.992418. Epub 2014 Dec 12.

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.

Clin Breast Cancer. 2010 Dec 1;10(6):489-91. doi: 10.3816/CBC.2010.n.065.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.

Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis .

Int J Clin Pharmacol Ther. 2017 Sep;55(9):720-727. doi: 10.5414/CP202921.

HER2-positive breast cancer: update on Breast Cancer International Research Group trials.

Clin Breast Cancer. 2002 Oct;3 Suppl 2:S75-9. doi: 10.3816/cbc.2002.s.016.

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Lancet Oncol. 2017 Jan;18(1):52-62. doi: 10.1016/S1470-2045(16)30631-3. Epub 2016 Dec 7.

A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.

Hum Pathol. 2004 Mar;35(3):379-81. doi: 10.1016/j.humpath.2003.05.003.

Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.

Am J Health Syst Pharm. 2013 Sep 15;70(18):1579-87. doi: 10.2146/ajhp120735.

引用本文的文献

Physicians' knowledge, practice, and attitudes on fertility and pregnancy-related issues in young women with advanced breast cancer: results of the ABC6 and ABC7 survey.

Breast. 2025 Apr 24;82:104479. doi: 10.1016/j.breast.2025.104479.

Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.

Breast Cancer Res Treat. 2024 Jun;205(2):287-302. doi: 10.1007/s10549-023-07235-0. Epub 2024 Feb 21.

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon.

Explor Target Antitumor Ther. 2021;2(2):139-155. doi: 10.37349/etat.2021.00037. Epub 2021 Apr 30.

No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.

Br J Cancer. 2022 Apr;126(6):881-888. doi: 10.1038/s41416-021-01676-4. Epub 2021 Dec 20.

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer.

Pharmaceutics. 2020 Oct 19;12(10):986. doi: 10.3390/pharmaceutics12100986.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Is HER2-positive metastatic breast cancer still an incurable disease?

作者信息

Lambertini Matteo, Vaz-Luis Ines

机构信息

Department of Medical Oncology, Institut Gustave Roussy, Université Paris-Saclay, Inserm, Biomarqueurs Prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, Villejuif, France.